By Ethan Covey
A small number of patients who were treated for mpox with tecovirimat (TPOXX, SIGA Technologies) have developed new skin or mucosal lesions post-therapy, according to the CDC.
From August through September 2022, nine such cases were analyzed among people in New York City (MMWR Morb Mortal Wkly Rep 2023;72:471-472).
“This report is the first to describe this phenomenon of mpox post-treatment lesions in detail,” Leah Seifu, MD, a CDC epidemic intelligence service